Journal
CURRENT OPINION IN BIOTECHNOLOGY
Volume 48, Issue -, Pages 127-134Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2017.03.010
Keywords
-
Funding
- National Institutes of Health [U19 AI109662, 1DP2HD08406901]
Ask authors/readers for more resources
The development of broad-spectrum, host-acting antiviral therapies remains an important but elusive goal in anti-infective drug discovery. To replicate efficiently, viruses not only depend on their hosts for an adequate supply of pyrimidine nucleotides, but also up-regulate pyrimidine nucleotide biosynthesis in infected cells. In this review, we outline our understanding of mammalian de novo and salvage metabolic pathways for pyrimidine nucleotide biosynthesis. The available spectrum of experimental and FDA-approved drugs that modulate individual steps in these metabolic pathways is also summarized. The logic of a host-acting combination antiviral therapy comprised of inhibitors of dihydroorotate dehydrogenase and uridine/cytidine kinase is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available